ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541) has released an update.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has announced the IND approval for Phase Ib/III clinical trials of IMC-002, aimed at treating neuromyelitis optica spectrum disorders and systemic lupus erythematosus. The company has also highlighted that it holds the global intellectual property and commercial rights for IMC-002, a bispecific molecule designed for enhanced therapeutic outcomes in malignant B cells. However, the company cautions shareholders and potential investors that the successful development and marketing of IMC-002 cannot be guaranteed.
For further insights into HK:1541 stock, check out TipRanks’ Stock Analysis page.
